» Articles » PMID: 24452759

Mouse Models of Prostate Cancer: Picking the Best Model for the Question

Overview
Specialty Oncology
Date 2014 Jan 24
PMID 24452759
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?

Citing Articles

Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.

Wang X, Ma S, Twardowski P, Lau C, Chan Y, Wong K Clin Transl Med. 2024; 14(10):e70048.

PMID: 39390760 PMC: 11467013. DOI: 10.1002/ctm2.70048.


Emerging Perspectives in Zinc Transporter Research in Prostate Cancer: An Updated Review.

Acevedo S, Segovia M, De la Fuente-Ortega E Nutrients. 2024; 16(13).

PMID: 38999774 PMC: 11243615. DOI: 10.3390/nu16132026.


Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation.

Kostlan R, Phoenix J, Budreika A, Ferrari M, Khurana N, Choi J Mol Cancer Res. 2024; 22(9):826-839.

PMID: 38820127 PMC: 11372372. DOI: 10.1158/1541-7786.MCR-23-0904.


Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.

Kaushal J, Takkar S, Batra S, Siddiqui J Cancer Lett. 2024; 593:216954.

PMID: 38735382 PMC: 11799897. DOI: 10.1016/j.canlet.2024.216954.


In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.

Arriaga J, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, Afari S, Chhouri H Oncogene. 2024; 43(17):1303-1315.

PMID: 38454137 PMC: 11101692. DOI: 10.1038/s41388-024-02995-5.


References
1.
Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

2.
Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

3.
Guo Y, Jacobs S, Kyprianou N . Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer. 1997; 71(4):573-9. DOI: 10.1002/(sici)1097-0215(19970516)71:4<573::aid-ijc11>3.0.co;2-d. View

4.
Suzuki A, de la Pompa J, Stambolic V, Elia A, Sasaki T, del Barco Barrantes I . High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998; 8(21):1169-78. DOI: 10.1016/s0960-9822(07)00488-5. View

5.
Floch N, Kinkade C, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A . Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res. 2012; 72(17):4483-93. PMC: 3432676. DOI: 10.1158/0008-5472.CAN-12-0283. View